Evidence map›Paper›PMID 40050778›Full record

ArticleBMC cancer2025

Impact of celastrol on mitochondrial dynamics and proliferation in glioblastoma.

Lei Liang, Wenying Lv, Gang Cheng, Mou Gao, Junzhao Sun, Ning Liu, Hanbo Zhang, Baorui Guo, Jiayu Liu, Yanteng Li and 4 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lei Liang *Medical School of Chinese PLA, Beijing, 100853, China.
Wenying Lv *Department of Neurosurgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
Gang ChengDepartment of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Mou GaoDepartment of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Junzhao SunDepartment of Neurosurgery, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, 100048, China.
Ning LiuDepartment of Neurosurgery, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, 100010, China.
Hanbo ZhangMedical School of Chinese PLA, Beijing, 100853, China.
Baorui GuoMedical School of Chinese PLA, Beijing, 100853, China.
Jiayu LiuDepartment of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Yanteng LiMedical School of Chinese PLA, Beijing, 100853, China.
Shengqiang XieMedical School of Chinese PLA, Beijing, 100853, China.
Jiangting WangXiangyang Central Hospital, Xiangyang, 441106, China.
Junru HeiDepartment of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China.
Jianning ZhangMedical School of Chinese PLA, Beijing, 100853, China. jnzhang2024_ll@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTargeting mitochondrial dynamics offers promising strategies for treating glioblastoma multiforme. Celastrol has demonstrated therapeutic effects on various cancers, but its impact on mitochondrial dynamics in glioblastoma multiforme remains largely unknown. We studied the effects of Celastrol on mitochondrial dynamics, redox homeostasis, and the proliferation.

methodsMito-Tracker Green staining was conducted on U251, LN229, and U87-MG cells to evaluate the effects of Celastrol on mitochondrial dynamics. The Western blot analysis quantified the expression levels of mitochondrial dynamin, antioxidant enzymes, and cell cycle-related proteins. JC-1 staining was performed to discern mitochondrial membrane potential. Mitochondrial reactive oxygen species were identified using MitoSOX. The proliferative capacity of cells was assessed using Cell Counting Kit-8 analysis, and colony formation assays. Survival analysis was employed to evaluate the therapeutic efficacy of Celastrol in C57BL/6J mice with glioblastoma.

resultsOur findings suggest that Celastrol (1 and 1.5 µM) promotes mitochondrial fission by downregulating the expression of mitofusin-1. A decrease in mitochondrial membrane potential at 1 and 1.5 µM indicates that Celastrol impaired mitochondrial function. Concurrently, an increase in mitochondrial reactive oxygen species and impaired upregulation of antioxidant enzymes were noted at 1.5 µM, indicating that Celastrol led to an imbalance in mitochondrial redox homeostasis. At both 1 and 1.5 µM, cell proliferation was inhibited, which may be related to the decreased expression levels of Cyclin-dependent kinase 1 and Cyclin B1. Celastrol extended the survival of GBM-afflicted mice.

conclusionCelastrol promotes mitochondrial fission in glioblastoma multiforme cells by reducing mitofusin-1 expression, accompanying mitochondrial dysfunction, lower mitochondrial membrane potential, heightened oxidative stress, and decreased Cyclin-dependent kinase 1 and Cyclin B1 levels. This indicates that Celastrol possesses potential for repurposing as an agent targeting mitochondrial dynamics in glioblastoma multiforme, warranting further investigation.

Indexed as

Brain NeoplasmsGlioblastomaMitochondrial DynamicsTriterpenesAnimalsCell Line, TumorCell ProliferationHumansMembrane Potential, MitochondrialMiceMice, Inbred C57BLMitochondriaPentacyclic TriterpenesReactive Oxygen SpeciesXenograft Model Antitumor AssayscelastrolPentacyclic TriterpenesReactive Oxygen SpeciesTriterpenesCDK1 proteinCelastrolDrug repurposingGlioblastomaMitochondrial dynamicsOxidative stress

Identifiers

PMID40050778
PMCPMC11887396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.